Immupharma PLC Grant of Options (0005A)
December 21 2017 - 2:05AM
UK Regulatory
TIDMIMM
RNS Number : 0005A
Immupharma PLC
21 December 2017
21 DECEMBER 2017
ImmuPharma PLC
("ImmuPharma" or the "Company")
Grant of Options
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, announces the
approval of the grant of options over a total of 900,000 ordinary
shares of 10p each in the Company ("Ordinary Shares") to certain of
its consultants who have been directly involved in Lupuzor(TM)'s
successful development to date, representing 0.679% of ImmuPharma's
Ordinary Shares and total voting rights on a fully diluted basis
(the "Options"). The Options were granted upon the recommendation
of the Company's remuneration committee.
The exercise price for the Options is 153 pence being the
closing middle market share price on 20 December 2017. The Options
will vest subject to certain conditions after three years and are
exercisable between three and ten years from the date of grant.
Total Share Options
The total options outstanding under both the 2017 Plan and the
Company's previous share option plan is 10,130,000, representing
7.64% of ImmuPharma's Ordinary Shares and total voting rights on a
fully diluted basis. The total options outstanding that have been
granted to non-employees and consultants is 6,085,000. The total
warrants outstanding is 153,850. Taken altogether, there are
currently 16,368,850 outstanding options and warrants, representing
12.35% of ImmuPharma's Ordinary Shares and total voting rights on a
fully diluted basis.
This announcement contains inside information for the purpose of
Article 7 of Regulation (EU) 596/2014.
Ends
For further information, please contact:
ImmuPharma plc (www.immupharma.co.uk)
--------------------------------------- ---------------------
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor +44 (0) 20 7152
Relations 4080
Twitter: @immupharma +44 (0) 7721 413496
--------------------------------------- ---------------------
Northland Capital Partners Limited
(NOMAD & Broker)
Patrick Claridge, Corporate
Finance
David Hignell, Corporate Finance
Jamie Spotswood, Corporate Finance +44 (0) 20 3861
Rob Rees, Corporate Broking 6625
--------------------------------------- ---------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCTMBPTMBJTBAR
(END) Dow Jones Newswires
December 21, 2017 02:05 ET (07:05 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Sep 2023 to Sep 2024